PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:		NEW ASSIGNMENT		
NATURE OF CONVEYANCE:		ASSIGNMENT	ASSIGNMENT	
CONVEYING PARTY	DATA			
[
N		Name	Execution Date	
Henning Steinhagen			04/27/2009	
Markus Follmann			05/08/2009	
Jochen Goerlitzer			04/27/2009	
Herman Schreuder			04/27/2009	
RECEIVING PARTY D	ΑΤΑ			
Name:	sanofi-aventi	sanofi-aventis		
Street Address:	174 Avenue	de France		
City:	Paris			
State/Country:	FRANCE			
Postal Code:				
PROPERTY NUMBER	RS Total: 1			08100761
Property Type			Number	
Property Ty	уре	Number		, C
Property Ty Application Number:	уре	Number 12400189		
Application Number:	DATA	12400189		
Application Number: CORRESPONDENCE Fax Number:	DATA (908)23	12400189		
Application Number: CORRESPONDENCE Fax Number:	DATA (908)23	12400189 1-2626 Mail when the fax attempt is unsuccessful.		
Application Number: CORRESPONDENCE Fax Number: <i>Correspondence will b</i>	DATA (908)23 be sent via US 908-231	12400189 1-2626 Mail when the fax attempt is unsuccessful.		
Application Number: CORRESPONDENCE Fax Number: <i>Correspondence will E</i> Phone: Email: Correspondent Name:	DATA (908)23 be sent via US 908-231 linda.rer	12400189 1-2626 <i>Mail when the fax attempt is unsuccessful.</i> -2551 ner@sanofi-aventis.com		
Application Number: CORRESPONDENCE Fax Number: <i>Correspondence will L</i> Phone: Email: Correspondent Name: Address Line 1:	DATA (908)23 be sent via US 908-231 linda.rer Ronald 1041 Ro	12400189 1-2626 <i>Mail when the fax attempt is unsuccessful.</i> -2551 ner@sanofi-aventis.com G. Ort pute 202-206		
Application Number: CORRESPONDENCE Fax Number: <i>Correspondence will E</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 2:	DATA (908)23 be sent via US 908-231 linda.rer : Ronald 1041 Ro Mail Coo	12400189 1-2626 <i>Mail when the fax attempt is unsuccessful.</i> -2551 ner@sanofi-aventis.com G. Ort pute 202-206 de: D303-A		
Application Number: CORRESPONDENCE Fax Number: <i>Correspondence will L</i> Phone: Email: Correspondent Name: Address Line 1:	DATA (908)23 be sent via US 908-231 linda.rer : Ronald 1041 Ro Mail Coo	12400189 1-2626 <i>Mail when the fax attempt is unsuccessful.</i> -2551 ner@sanofi-aventis.com G. Ort pute 202-206		
Application Number: CORRESPONDENCE Fax Number: <i>Correspondence will E</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 2:	DATA (908)23 be sent via US 908-231 linda.rer Ronald 1041 Ro Mail Coo Bridgew	12400189 1-2626 <i>Mail when the fax attempt is unsuccessful.</i> -2551 ner@sanofi-aventis.com G. Ort pute 202-206 de: D303-A		
Application Number: CORRESPONDENCE Fax Number: <i>Correspondence will E</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 2: Address Line 4:	DATA (908)23 be sent via US 908-231 linda.rer Ronald 1041 Ro Mail Coo Bridgew	12400189 1-2626 <i>Mail when the fax attempt is unsuccessful.</i> -2551 ner@sanofi-aventis.com G. Ort bute 202-206 de: D303-A ater, NEW JERSEY 08807		

500964654

PATENT REEL: 023243 FRAME: 0236

source=DE2006034 Assignments#page1.tif source=DE2006034 Assignments#page2.tif source=DE2006034 Assignments#page3.tif

> PATENT REEL: 023243 FRAME: 0237

DE2006/034 US CNT

<u>A S S I G N M E N T</u>

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

1) Dr. Henning Steinhagen, Starkeradweg 21, 65843 Sulzbach, Germany

2) Dr. Markus Follmann, Ringstr. 61, 42489 Wülfrath Germany

3) Dr. Jochen Goerlitzer, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany

4) Dr. Herman Schreuder, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany

The inventors are citizens of: 1-3) Germany; 4) Netherlands

hereby sell, assign, and transfer unto sanofi-aventis, a corporation organized under the laws of France, located at 174 avenue de France, 75013 Paris, France,

the entire right, title and interest in and to my/our application for Letters Patent of the United States, executed concurrently herewith

Ser.-No.: 12/400189

March 9, 2009 filed:

ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS entitled:

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application for Letters Patent, and in and to all divisional or continuation applications that may be filed for United States Letters Patent for any of said inventions, and in and to all patents that may be granted on the foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

Inventor(s): 1st. Hearing Hainegen	00/1000
1st. Healing Alushagen	Date: 27/4/09
2 nd :	Date:
3 rd :	Date:
4 th :	Date:

PATENT REEL: 023243 FRAME: 0238

DE2006/034 US CNT

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

1) Dr. Henning Steinhagen, Starkeradweg 21, 65843 Sulzbach, Germany

2) Dr. Markus Follmann, Ringstr. 61, 42489 Wülfrath Germany

3) Dr. Jochen Goerlitzer, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany

4) Dr. Herman Schreuder, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany

The inventors are citizens of: 1-3) Germany; 4) Netherlands

hereby sell, assign, and transfer unto **sanofi-aventis**, a corporation organized under the laws of **France**, located at **174 avenue de France**, **75013 Paris, France**,

the entire right, title and interest in and to my/our application for Letters Patent of the United States, executed concurrently herewith

Ser.-No.: 12/400189

filed: March 9, 2009

entitled: ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application for Letters Patent, and in and to all divisional or continuation applications that may be filed for United States Letters Patent for any of said inventions, and in and to all patents that may be granted on the foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

Inventor(s):

1 st :		Date:
2 nd :	Mahy For	Date: 518/ 200 9
3 rd :	/	Date:
4 th :		Date:

DE2006/034 US CNT

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

1) Dr. Henning Steinhagen, Starkeradweg 21, 65843 Sulzbach, Germany

2) Dr. Markus Follmann, Ringstr. 61, 42489 Wülfrath Germany

3) Dr. Jochen Goerlitzer, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany

4) Dr. Herman Schreuder, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany

The inventors are citizens of: 1-3) Germany; 4) Netherlands

hereby sell, assign, and transfer unto sanofi-aventis, a corporation organized under the laws of France, located at 174 avenue de France, 75013 Paris, France,

the entire right, title and interest in and to my/our application for Letters Patent of the United States, executed concurrently herewith

Ser.-No.: 12/400189

March 9, 2009 filed:

ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS entitled:

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application for Letters Patent, and in and to all divisional or continuation applications that may be filed for United States Letters Patent for any of said inventions, and in and to all patents that may be granted on the foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

Inventor(s):

1 st :		Date:
2 nd :	¢.	Date:
	Jorlin Lichter	Date: 27. 4.08
	Jama Silren dr	Date:

RECORDED: 09/17/2009